Chugai Seiyaku Kabushiki Kaisha

Hoffmann-la Roche Inc.

Shu Feng

Shu Wen Samantha Ho

Tomoyuki Igawa

Guy Georges

Tilman Schlothauer

Hubert Kettenberger

Joerg Moelleken

Georg Tiefenthaler

Jens Fischer

Gregor Jordan

Anton Jochner

Meher Majety

Valeria Runza

Sotaro Naoi

Martin Schaefer

Wei Shiong Adrian Ho

Michael Gertz

Runyi Adeline Lam

Maria Viert

Siok Wan Gan

Hirotake Shiraiwa

Taichi Kuramochi

Noriyuki Takahashi

Masaru Muraoka

An antigen-binding molecule capable of binding to multiple different antigens (e.g., CD3 on T cells, and CD137 on T cells, NK cells, DC cells, and/or the like), but does not nonspecifically crosslink two or more immune cells such as T cells is provided. Such multispecific antigen-binding molecule is capable of modulating and/or activating an immune response while circumventing the cross-linking between different cells (e.g., different T cells) resulting from the binding of a conventional multispecific antigen-binding molecule to antigens expressed on the different cells, which is considered to be responsible for adverse reactions when the multispecific antigen-binding molecule is used as a drug.

Antigen-binding molecule comprising altered antibody variable region

The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Bispecific anti-CCL2 antibodies

The invention provides anti-C1s antibodies and methods of using the same. The affinities of the antibodies to C1s depend on pH and other conditions. The invention also provides pharmaceutical formulations comprising the antibodies, and methods of treating an individual having a complement-mediated disease or disorder comprising administering the antibody to the individual. In addition, the binding affinity of the antibody at high and low pH was measured, and mice PK study was conducted on the antibodies, and pharmacokinetics parameters of the antibodies were evaluated in this application.

Anti-C1S antibodies and methods of use

The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

CD137- and DLL3-targeting multispecific antigen-binding molecules

CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereof

Growing community of inventors

Singapore, Singapore

Shu Feng